Lilly announces plan to expand global access to health care

pharmafile | October 19, 2016 | News story | Research and Development Eli Lilly, Lilly 30x30, global health 

Eli Lilly has announced a project, known as Lilly 30×30, which is a five-year, $90 million investment to improve access to treatments for diabetes, cancer and tuberculosis. The aim of the project being to reach 30 million people in resource-limited settings annually by 2030 with improved access to aforementioned treatments.

The work will see them expand current operations in Brazil, China, India, Kenya, Mexico, Russia South Africa and the US. Lilly will explore new approaches within different areas of its business, including: “initiatives to strengthen health systems and local treatment capacity in communities with significant gaps in care; patient education programs; collaboration on drug discovery for diseases disproportionately affecting people in resource-limited settings; product delivery and packaging more appropriate for people in resource-limited settings and innovative business models, including alternative product pricing strategies to improve access to care.”

Speaking on the project, John C. Lechleiter, Ph.D., Lilly chairman, president and CEO, stated: “Over the last two decades, we have made tremendous progress in expanding access to quality care in poorer communities, but we can and must do more. Lilly 30×30 is a company-wide mandate to achieve a six-fold increase in the number of people we reach annually, outside of our traditional business,” said John C. Lechleiter, Ph.D., Lilly chairman, president and CEO.

Lechleiter continued, “We will engage the entire Lilly organization to ensure that our aspirational goals are met. The investments announced today will help millions more benefit from Lilly’s life-saving work and accelerate our contributions toward the U.N. Sustainable Development Goals.”

Ben Hargreaves

Related Content


Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s …

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for …


Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials

Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C …

Latest content